Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

Multiple sclerosis (MS) could be "on the brink of a new class of treatment" after early trial results suggest two drugs may ...

Researchers have identified two experimental medications that may be able to promote myelin repair in people with MS, a study ...

Researchers have identified two compounds, K102 and K110, that could repair the nerve damage from multiple sclerosis. These ...

Multiple sclerosis, which affects around one in 500 people in Switzerland, is an autoimmune disease in which immune cells ...

With over 1 million Americans affected by multiple sclerosis (MS), we wanted to learn more about its symptoms, particularly ...

A new study found that most therapies used to treat multiple sclerosis (MS) were linked to a higher risk of low birth weight but not miscarriage, premature birth, and major birth defects. The study ...

Novartis won approval for its multiple sclerosis drug Mayzent, which will launch at a price of $88,000 annually, according to Reuters. 1. Mayzent, an oral drug, was approved for adults with relapsing ...

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...

Patients suspecting they have multiple sclerosis (MS) are encountering significant delays in accessing specialist care, with ...

Andrew Wolf, MD, discusses the growing costs, treatment advances, and geographic disparities in multiple sclerosis care.